Treatment of Postpartum Depression: Clinical and Pharmacological Options

Postpartum depression (PPD) is a common complication of childbearing, and has increasingly been identified as a major public health problem Clinical study have consistently shown that selective serotonin reuptake inhibitors (SSRIs) are effective in treating postpartum depression (PPD). In fact, SSRIs are considered a first-line treatment option for PPD due to their efficacy and relatively safe profile during breastfeeding. Untreated maternal depression has multiple potential negative effects on maternal-infant attachment and child development. Screening for depression in the perinatal period is feasible in multiple primary care or obstetric settings, and can help identify depressed mothers earlier. However, there are multiple barriers to appropriate treatment, including concerns about medication effects in breastfeeding infants. This article reviews the literature and recommendations for the treatment of postpartum depression, with a focus on the range of pharmacological, psychotherapeutic, and other nonpharmacologic interventions.

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2025-03-01
DOI
https://doi.org/10.5281/zenodo.14953989
Primary Topic
Maternal Mental Health During Pregnancy and Postpartum
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Treatment of Postpartum Depression: Clinical and Pharmacological Options

Zenodo (CERN European Organization for Nuclear Research)
Maternal Mental Health During Pregnancy and Postpartum
article

Treatment of Postpartum Depression: Clinical and Pharmacological Options

article en

Abstract

Postpartum depression (PPD) is a common complication of childbearing, and has increasingly been identified as a major public health problem Clinical study have consistently shown that selective serotonin reuptake inhibitors (SSRIs) are effective in treating postpartum depression (PPD). In fact, SSRIs are considered a first-line treatment option for PPD due to their efficacy and relatively safe profile during breastfeeding. Untreated maternal depression has multiple potential negative effects on maternal-infant attachment and child development. Screening for depression in the perinatal period is feasible in multiple primary care or obstetric settings, and can help identify depressed mothers earlier. However, there are multiple barriers to appropriate treatment, including concerns about medication effects in breastfeeding infants. This article reviews the literature and recommendations for the treatment of postpartum depression, with a focus on the range of pharmacological, psychotherapeutic, and other nonpharmacologic interventions.

Zenodo (CERN European Organization for Nuclear Research)
Good health and well-being
Openalex Percentile: Top 47%
Maternal Mental Health During Pregnancy and Postpartum
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Treatment of Postpartum Depression: Clinical and Pharmacological Options · Zenodo (CERN European Organization for Nuclear Research) (2025) | TGRS Research Map | TGRS